Cost-effectiveness of N-terminal pro-b-type natriuretic-guided therapy in elderly heart failure patients. Results from TIME-CHF (Trial of intensified versus standard medical therapy in elderly patients with congestive heart failure)

JACC: Heart Failure

Volumn 1, Issue 1, 2013, Pages 64-71

  Sanders van Wijk, Sandra ^a   van Asselt, Antoinette D I ^a   Rickli, Hans ^b   Estlinbaum, Werner ^c   Erne, Paul ^d   Rickenbacher, Peter ^e   Vuillomenet, Andre ^f   Peter, Martin ^g   Pfisterer, Matthias E ^h   Brunner La Rocca, Hans Peter ^a,h  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Maastricht University Medical Center ^*  (Switzerland)

^c Kantonsspital Liestal   (Switzerland)

^d Cardiology Department   (Switzerland)

^e University Hospital Bruderholz   (Switzerland)

^f Cardiology   (Switzerland)

^g Spital Thun   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cost effectiveness; Heart failure; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARDIOTONIC AGENT; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; ELDERLY CARE; FEMALE; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE PLANNING; HEART STROKE VOLUME; HOME FOR THE AGED; METABOLISM; MULTICENTER STUDY; NURSING HOME; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; UTILIZATION;

AGED; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; COST SAVINGS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH RESOURCES; HEART FAILURE; HOMES FOR THE AGED; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NURSING HOMES; PEPTIDE FRAGMENTS; QUALITY-ADJUSTED LIFE YEARS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84877960117     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2012.08.002     Document Type: Article

References (31)

1. Bundkirchen A., Schwinger R.H.G. Epidemiology and economic burden of chronic heart failure. Eur Heart J Suppl 2004, 6:D57-D60.
2. McMurray J.J., Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000, 83:596.
3. Feldman A.M., de Lissovoy G., Bristow M.R., et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005, 46:2311-2321.
4. Sanders G.D., Hlatky M.A., Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005, 353:1471-1480.
5. Doshi J.A., Glick H.A., Polsky D. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. Value Health 2006, 9:334-340.
6. Felker G.M., Hasselblad V., Hernandez A.F., O' Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422-430.
7. Porapakkham P., Zimmet H., Billah B., Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Int Med 2010, 170:507-514.
8. Pfisterer M., Buser P., Rickli H., et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009, 301:383-392.
9. Lainchbury J.G., Troughton R.W., Strangman K.M., et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol 2009, 55:53-60.
10. Adlbrecht C., Huelsmann M., Berger R., et al. Cost analysis and cost effectiveness of NT proBNP guided heart failure specialist care in addition to home based nurse care. Eur J Clin Invest 2011, 41:315-322.
11. Morimoto T., Hayashino Y., Shimbo T., Izumi T., Fukui T. Is B-type natriuretic peptide-guided heart failure management cost-effective?. Int J Cardiol 2004, 96:177-181.
12. Brunner-La Rocca H.P., Buser P.T., Schindler R., Bernheim A., Rickenbacher P., Pfisterer M. Management of elderly patients with congestive heart failure-design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 2006, 151:949-955.
13. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:1115-1140.
14. Brazier J., Roberts J., Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21:271-292.
15. TARMED Suisse. Bern, Switzerland. [Website]. Available at: Accessed November 21, 2012. http://www.tarmedsuisse.ch.
16. Medicines Compendium of Switzerland. Available at: Accessed December 2012. http://www.kompendium.ch.
17. Briggs A.H., O' Brien B.J., Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Ann Rev Public Health 2002, 23:377-401.
18. Briggs A.H., Wonderling D.E., Mooney C.Z. Pulling cost effectiveness analysis up by its bootstraps: a non parametric approach to confidence interval estimation. Health Econ 1997, 6:327-340.
19. Severens J.L., Brunenberg D.E.M., Fenwick E.A.L., OBrien B., Joore M.A. Cost-effectiveness acceptability curves and a reluctance to lose. Pharmacoeconomics 2005, 23:1207-1214.
20. Mueller C., Laule-Kilian K., Schindler C., et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006, 166:1081-1087.
21. Siebert U., Januzzi J.L., Beinfeld M.T., Cameron R., Gazelle G.S. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 2006, 98:800-805.
22. Heidenreich P.A., Gubens M.A., Fonarow G.C., Konstam M.A., Stevenson L.W., Shekelle P.G. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004, 43:1019-1026.
23. Liao L., Allen L.A., Whellan D.J. Economic burden of heart failure in the elderly. Pharmacoeconomics 2008, 26:447-462.
24. Weintraub W.S., Cole J., Tooley J.F. Cost and cost-effectiveness studies in heart failure research. Am Heart J 2002, 143:565-576.
25. Reed S.D., Whellan D.J., Li Y., et al. Economic evaluation of the HF-ACTION (heart failure: a controlled trial investigating outcomes of exercise training) randomized controlled trial: an exercise training study of patients with chronic heart failure. Circ Cardiovasc Qual Outcomes 2010, 3:374-381.
26. Smith B., Hughes-Cromwick P.F., Forkner E., Galbreath A.D. Cost-effectiveness of telephonic disease management in heart failure. Am J Manag Care 2008, 14:106-115.
27. Hebert P.L., Sisk J.E., Wang J.J., et al. Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community. Ann Intern Med 2008, 149:540-548.
28. Chan D.C., Heidenreich P.A., Weinstein M.C., Fonarow G.C. Heart failure disease management programs: a cost-effectiveness analysis. Am Heart J 2008, 155:332-338.
29. Miller G., Randolph S., Forkner E., Smith B., Galbreath A.D. Long-term cost-effectiveness of disease management in systolic heart failure. Med Decis Making 2009, 29:325-333.
30. Turner D.A., Paul S., Stone M.A., Juarez-Garcia A., Squire I., Khunti K. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care. Heart 2008, 94:1601-1606.
31. Devlin N., Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004, 13:437-452.